John Childs, a director at Biohaven Pharmaceutical (BHVN), recently made a 13,157 share buy. The purchase came to just under $1 million even, and increased the director’s stake by just over 0.5 percent.
That’s the second buy from Childs this month following a 10,000 share buy earlier. Insiders have been both buyers and sellers in the past year, with sellers leading on total shares. Overall, insiders own nearly 14 percent of the company.
A biotech firm targeting neurological diseases, the company has a number of products available, as well as some prospective new treatments in trial.
- 2021’s Hottest Electric Vehicle Stocks – Yours Free
This year could be the biggest one yet for the unstoppable electric vehicle megatrend — but if you’re looking to take advantage, the time to act is now.
That’s why Luke Lango has just released his picks for the 11 best EV stocks of 2021. Each one has been hand-selected for its potential to deliver life-changing profits as electric vehicles continue to disrupt the automotive industry.
Shares are up 140 percent over the past year, more than twice the return of the S&P 500. As an early-stage biotech company, the firm is currently unprofitable.
Action to take: While insiders have a mixed trading record, the relatively high percentage of insider ownership bodes well for prospective investors. Shares have traded as high as $100 in the past year, and look like a better entry point around $70, especially as insiders are starting to buy in here.
On a technical basis, shares are looking oversold and have dropped well under the major moving averages. A short-term bounce higher could lead to a jump in the July $80 calls. With a bid/ask spread of $6.05, traders could likely nab mid-to-high double-digit returns on the trade before expiration.